Selected angle: counter_signal

One-sentence thesis

The number of days in hospital was 41% lower in the triplet regimen than in the historical cohort (13 vs 22 days; P < .01). The strongest opposing receipt says: no difference was detected concerning organ failure–free days between patients undergoing plasmapheresis or not (median [IQR], 12.0 [8.0-14.0] vs 13.0 [8.0-14.0]; P = .94).

Interpretation note: This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.

Why this is surprising

The value is the collision between receipts, not the isolated positive finding; this is the branch worth testing next.

Evidence receipts

• fact_id=99848 (A_core) — The number of days in hospital was 41% lower in the triplet regimen than in the historical cohort (13 vs 22 days; P < .01). doi=10.1182/blood.2020008021
• fact_id=99847 (A_core) — Patients from this cohort experienced less exacerbations (3.4% vs 44%, P < .01). doi=10.1182/blood.2020008021
• fact_id=134946 (A_core) — the use of TPE in patients with ADAMTS13 activity >10% varied significantly across the institutions in our consortium (13·2-63·8%, P < 0·0001). doi=10.1111/bjh.13658
• fact_id=99845 (A_core) — The percentage of patients in the triplet regimen with the composite primary outcome was 2.2% vs 12.2% in historical patients (P = .01). doi=10.1182/blood.2020008021
• fact_id=136356 (A_core) — her ADAMTS13 activity was 19% doi=10.1111/bjh.17782
• fact_id=138308 (A_core) — At 90 days, the survival rate of ALSS group was higher than that of the control group (62/104 [60%] vs 61/130 [47%], respectively; P<0.05). doi=10.1097/md.0000000000000338
• fact_id=156850 (A_core) — no difference was detected concerning organ failure–free days between patients undergoing plasmapheresis or not (median [IQR], 12.0 [8.0-14.0] vs 13.0 [8.0-14.0]; P = .94) doi=10.1001/jamanetworkopen.2023.20802

Context receipts

Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim.

• fact_id=99846 (B_context) — they recovered durable platelet count 1.8 times faster than historical patients (95% confidence interval, 1.41-2.36; P < .01). doi=10.1182/blood.2020008021
• fact_id=138959 (B_context) — a 33.3% reduction in the median number of therapeutic plasma exchange days (5.0 vs 7.5 days) vs placebo. doi=10.1182/bloodadvances.2020001834
• fact_id=162455 (B_context) — Common treatments included antiseizure medications (median 5), general anesthesia, and immunotherapy such as corticosteroids, intravenous immunoglobulin, and plasma exchange. doi=10.1111/epi.17523

What this changes

Treat this as a focused working signal, not a broad topic claim. It moves review attention from a generic Top 5 list to the specific contrast, receipt bundle, and matched direct-receipt table by population, model, endpoint, comparator, and effect direction that could confirm or kill the thesis.

Limitations

• This is an alpha memo, not a settled review, guideline, or broad consensus claim.
• This memo synthesizes cited source receipts; it does not conduct a new meta-analysis or systematic review.
• Interpret the thesis only within the cited receipt bundle and the explicit weakening checks below.
• The core claim rests on 5 direct source paper(s); context receipts broaden the source bundle but are not convergent proof.
• Independent receipts fail to reproduce the claimed contrast.
• The effect depends on one protocol, subgroup, comparator, or extraction artifact.

What would weaken this

• Independent receipts fail to reproduce the claimed contrast.
• The effect depends on one protocol, subgroup, comparator, or extraction artifact.

Strongest counter-evidence

• fact_id=156850 (A_core) — no difference was detected concerning organ failure–free days between patients undergoing plasmapheresis or not (median [IQR], 12.0 [8.0-14.0] vs 13.0 [8.0-14.0]; P = .94) Source: Early Plasmapheresis Among Patients With Hypertriglyceridemia–Associated Acute Pancreatitis

Next extraction

• Extract independent A_core/B_context receipts that test the lead contrast directly.
• Audit whether each direct receipt remains comparable on population, endpoint, comparator, and measurement method.
• Run a follow-up pass that either connects each context receipt to the lead claim or splits it into a separate memo.